Recombinant Proteins

Because AMD and linked diseases develop slowly over the course of many years, even minor deficiencies in certain proteins that result in only a modest decrease in the function of the protein, over time, can lead to the onset of disease.

When we have identified patients with a specific protein variant that is dysfunctional, we can compensate for that dysfunction by administering a recombinantly produced, fully functional version of the protein.

Though the technology behind the production of recombinant proteins is well-established, the individual characteristics of the protein being produced can present significant challenges.

Many recombinant versions of proteins are large and difficult to produce, Gemini has made significant advances in addressing the technical challenges of producing the recombinant proteins relevant to treatment of AMD and linked diseases.